MIP Discovery
MIP Discovery develops and manufactures molecularly imprinted polymers (MIPs) using its proprietary processes. MIPs are ‘synthetic’ affinity reagents that offer a high performance, more robust alternative to antibodies, for next generation IVD devices. MIPs typically have a similar or greater sensitivity and selectivity than antibodies, which has been validated with the companies 'showcase' COVID-19 product. The business is focused on respiratory, infectious disease and drugs of abuse testing.